3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
40
Breast Neoplasms
12
Prostatic Neoplasms
11
Fallopian Tube Neoplasms
10
Pancreatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
7
Glioblastoma
6
Neoplasm Metastasis
5
Carcinoma, Ovarian Epithelial
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Glioma
4
Small Cell Lung Carcinoma
3
Mesothelioma
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Interventions
Temozolomide
44
Radiotherapy
20
Magnetic Resonance Spectroscopy
13
Irinotecan
13
Carboplatin
11
Bevacizumab
11
Filgrastim
9
Surgical Procedures, Operative
7
Procarbazine
6
sargramostim
5
Vincristine
5
Imatinib Mesylate
5
Etoposide
5
Erlotinib Hydrochloride
5
Carmustine
5
Biopsy
5
etoposide phosphate
4
Peripheral Blood Stem Cell Transplantation
4
Lomustine
4
Immunohistochemistry
4
Cyclophosphamide
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
temsirolimus
3
poly ICLC
3
aldesleukin
3
Thalidomide
3
Surveys and Questionnaires
3
Radiation
3
Polymerase Chain Reaction
3
Gadolinium DTPA
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Oligodendroglioma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts